

Table S1. Demographics of Included Versus Excluded Participants.

Characteristic	Included Participants (N=10740)	Excluded Participants (N=1394)	p-value
Mean age (SD)	32.2 (17.5)	35.7 (17.1)	<0.001
Foreign-born	8685 (80.9%)	1093 (78.4%)	0.032
Close contact to TB case	991 (9.2%)	110 (7.9%)	0.11
HIV-seropositive	1370 (12.8%)	101 (7.2%)	<0.001

Table S2. Data Used to Calculate Prior Estimates of Sensitivity for the Tuberculin Skin Test and Interferon- γ Release (IGRA) Assays, with Progression to Active Tuberculosis as the Reference Standard.

Study	Group at High Risk	Country	Yr(s)	Duration of Follow-Up, Yrs	Total Subjects, No.	Positive QFT, No. (%)	Progressed to Active TB, No. (%)	QFT Sensitivity for All Cases of Active TB (%)	Positive TSPOT, No. (%)	Progressed to Active TB, No., (%)	TSPOT Sensitivity for All Cases of Active TB (%)
Zellweger et al. AJRCCM 2015 ¹	TB contacts	Low incidence European countries	2009–2011	≤2.5	5,020 3895 QFT 1,125 TSPOT	1,068/3,895 (27.4)	14/421 (3.3) w/o prev therapy 3/481 (0.6) w/ prev therapy	17/20 (85.0)	299/1125 (26.6)	2/73 (2.7) w/o prev therapy 0/208 (0) w/prev therapy	2/4 (50.0)
Diel et al. AJRCCM 2008 ²	TB contacts	Germany	2005–2006	2	601	66 (11.0)	6/41 (14.6)	6/6 (100)	N/A	N/A	N/A
Diel et al. AJRCCM 2011 ³ (update)	TB contacts	Germany	2005–2008	4	954	198 (20.8)	19/147 (12.9)	19/19 (100)	N/A	N/A	N/A
Hill et al. PLoS One 2008 ⁴	TB contacts	Gambia	2002–2004	2	2348	N/A	N/A	N/A	649/1736 (37.4)	11/649 (1.7)	11/21 (52.4)
Kik et al. Eur Respir J 2010 ⁵	TB contacts	The Netherlands	2005–2007	2	339	178/327 (54.4)	5/178 (2.8)	5/8 (62.5)	181/299 (60.5)	6/181 (3.3)	6/8 (75.0)
Lienhardt et al., PLoS One 2010 ⁶	TB contacts	Senegal	2004–2006	2	2679	N/A	N/A	N/A	544/952 (57.1)	17/544 (3.1)	17/23 (73.9)
Yoshiyama et al. IJTLD 2010 ⁷	TB contacts	Japan	2003–2005	2	3102	419/3,102 (13.5)	20/419 (4.8)	20/39 (51.3)	N/A	N/A	N/A
Higuchi et al. Resp 2007 ⁸	TB contacts (students)	Japan	2002	3.5	349	4/88 (4.5)	0/4 (0)	N/A	N/A	N/A	N/A
Bradshaw et al. PLoS One 2011 ⁹	TB contacts (health care workers)	Ireland	2007	3	389	37/389 (9.5)	0/37 (0)	N/A	N/A	N/A	N/A
Song et al. Chest 2012	TB contacts (high	Korea	2007	2	1,826	203/270 (75.2), but	11/203 (5.4)	11/11 (100)	N/A	N/A	N/A

Study	Group at High Risk	Country	Yr(s)	Duration of Follow-Up, Yrs	Total Subjects, No.	Positive QFT, No. (%)	Progressed to Active TB, No. (%)	QFT Sensitivity for All Cases of Active TB (%)	Positive TSPOT, No. (%)	Progressed to Active TB, No., (%)	TSPOT Sensitivity for All Cases of Active TB (%)
¹⁰	school)					only IGRA tested among 270/1,826 (14.8) with positive TST					
Bakir et al. Ann Intern Med 2008 ¹¹	Children TB contacts (aged 1–16 yrs)	Turkey	2002–2004	1.3	908	N/A	N/A	N/A	381 (42.0)	11/381 (2.9)	11/15 (73.3)
Kruczak et al. Scand J Infect Dis 2014 ¹²	Homeless, TB contacts, low risk groups	Krakow, Poland	2007–2009	4-5	785	211/779 (27.1)	8/211 (3.8)	8/12 (66.7)	N/A	N/A	N/A
Pullar et al. BMC ID 2014 ¹³	HIV-positive adults	Norway	2009–2010	2	304	77/298 (25.8)	0/77 (0)	N/A	29/117 (24.8)	0/29 (0)	N/A
Santin et al. Diagn Micro Infect Dis 2011 ¹⁴	HIV-positive adults	Spain	2007–2009	~2	135	13/135 (9.6)	0/13 (0)	N/A	N/A	N/A	N/A
Aichelburg et al. CID 2009 ¹⁵	HIV-positive adults	Austria	2006–2007	19 mos.	830	44 (5.3)	3/36 (8.3)	3/3 (100)	N/A	N/A	N/A
Jonnalagadda et al. J Inf Dis 2010 ¹⁶	HIV-positive pregnant women	Kenya	1999–2005	2	333	N/A	N/A	N/A	120/281 (42.7)	6/110 (5.5)	6/9 (66.7)
Lange et al. IJTLD 2012 ¹⁷	Immuno-compromised (only 11% HIV)	Germany	2006–2007	28 mos.	460	38(8.3)	1/38 (2.6)	1/1 (100)	N/A	N/A	N/A
Sester et al. AJRCCM 2014 ¹⁸	Immuno-compromised (50% HIV-positive)	11 European countries	2008–2011	5	1,537	239/1,423 (16.8)	3/215 (1.4)	3/8 (37.5)	266/1378 (19.3)	4/247 (1.6)	4/10 (40.0)
Lee et al. Infect 2009	End-stage renal	Taiwan	2005	2	32	12/30 (40.0)	1/12 (8.3)	1/1 (100)	15/32 (46.9)	0/15 (0)	0/2 (0)

Study	Group at High Risk	Country	Yr(s)	Duration of Follow-Up, Yrs	Total Subjects, No.	Positive QFT, No. (%)	Progressed to Active TB, No. (%)	QFT Sensitivity for All Cases of Active TB (%)	Positive TSPOT, No. (%)	Progressed to Active TB, No., (%)	TSPOT Sensitivity for All Cases of Active TB (%)
¹⁹	disease										
Chang et al. Clin Rheum 2011 ²⁰	Inflammatory arthritis	Korea	2007–2009	1.5	100	36/100 (36.0)	0/36 (0)	N/A	N/A	N/A	N/A
Leung et al. AJRCCM 2010 ²¹	Silicosis (males)	Hong Kong	2004–2008	2	308	N/A	N/A	N/A	204/308 (66.2)	15/204 (7.4)	15/17 (88.2)
Kim et al. Am J Transplant 2011 ²²	Kidney transplants	Korea	2008–2009	1.5	312	N/A	N/A	N/A	89/296 (30.1)	4/89 (4.5)	4/4 (100)
Harstad et al. IJTLD 2010 ²³	Asylum seekers	Norway	2005–2006	23–32 mos.	832	246 (29.9)	8/246 (3.3)	8/9 (88.9)	N/A	N/A	N/A
Mahomed et al. PLoS One 2011 ²⁴	Children aged 12–18 yrs	South Africa	2005–2009	3.8	5,244	2669/5244 (50.9)	39/2669 (0.3)	39/52 (75.0)	N/A	N/A	N/A
Schablon et al. BMC Infect Dis 2011 ²⁵	Nursing students	Germany	2008–2009	2	194	2/180 (1.1)	0/2 (0)	N/A	N/A	N/A	N/A
Mandalakas et al. AJRCCM 2015 ²⁶	Children TB contacts (3 mos.–15 years, 22% HIV-positive)	South Africa	2008–2012	3 mos.	1,343	520/1261 (41.2)	85/1343 (6.3)	54/76 (71.1)	302/991 (30.5)	85/1343 (6.3)	45/72 (62.5)

Abbreviations: LTBI = latent tuberculosis infection; N/A = not applicable; IGRA = interferon- γ release assay; QFT = QuantiFERON[®] Gold In-Tube; TB = tuberculosis; TSPOT = T-SPOT[®].TB

Table S3. Data Used to Calculate Prior Estimates of TST Sensitivity for Latent Tuberculosis Infection, with Progression to Active Tuberculosis as the Reference Standard

Study	Group at High Risk	Country	Yr(s)	Duration of Follow-Up	Subjects, No.	Positive TST, No. (%)	Progressed to Active TB, No. (%)	TST Sensitivity for All Cases of Active TB
Kik et al., Eur Respir J 2010 ⁵	Close Contacts (aged ≥ 16 yrs) HIV-positive excluded	Netherlands (8% born in Europe, 8% S. Am, 36% Asia, 46% Africa)	Apr 2005–Jul 2007	2 yrs	339 (only >5 mm TST were followed)	≥ 10 mm = 279 ≥ 15 mm = 177	9	≥ 10 mm = 9/9 (100%) ≥ 15 mm = 8/9 (88%)
Diel et al. AJRCCM 2008. Updated in Diel et al., AJRCCM 2011 ^{2,3}	Close Contacts (age 0–60 yrs)	Germany 59% German-born, 41% not German-born	May 2005–Apr 2008	≥ 2 yrs	954	≥ 5 mm = 604 (63%) ≥ 10 mm = 242 (25%)	19	≥ 5 mm = 17/19 (89%) ≥ 10 mm = 8/19 (42%)
Sackoff et al., IJTL D 2001 ²⁷	HIV-positive (median CD4 ⁺ 186)	U.S. (New York)	Jan 1995–Dec 1995	6–12 mos.	2,197	≥ 5 mm = 439	23	≥ 5 mm = 9/23 (39%)
Zhang et al. Chin Med J 2013 ²⁸	Healthcare workers	Beijing	Unknown	60 mos.	101	≥ 10 mm = 53	1	≥ 10 mm = 1/1 (100%)
Torres Costa et al., J Occup Med Toxicol 2011 ²⁹	Healthcare workers	Portugal	Jan 2007–Dec 2010	Mean 19 mos.	2,884	≥ 10 mm = 2,102	4	≥ 10 mm = 4/4 (100%)
Bakir et al. Annals 2008 ¹¹	Pediatric close contacts 1 mo.–16 yrs	Turkey	Oct 2002	Mean 1.3 yrs	908	≥ 5 mm = 550	15	≥ 5 mm = 12/15 (80%)
Chang et al. Clin Rheum 2011 ²⁰	Adults with arthritis	South Korea	Aug 2007–Jul 2009	Median 18 mos.	107	≥ 10 mm = 36	0	N/A

Study	Group at High Risk	Country	Yr(s)	Duration of Follow-Up	Subjects, No.	Positive TST, No. (%)	Progressed to Active TB, No. (%)	TST Sensitivity for All Cases of Active TB
Comstock et al. AJE 1974 ³⁰	Children 1–19 yrs	Puerto Rico	1949–1951	~19 yrs	191,827	≥6mm = 82,269	1,400	≥6 mm = 1400/1400 (100%)
Daley et al. AJRCCM 1998; ³¹	Adult intravenous drug users 30.5% HIV+	San Francisco	1990–1994	Median 22 mos.	1109	≥5 mm HIV-positive = 96 ≥10 mm HIV-negative = 336	8 (5 HIV-positive, 3 HIV-negative,)	HIV-positive = 3/5 (60%) HIV-negative = 2/3 (67%)
Del Corral et al. PLOS One 2009 ³²	Close Contacts (4% HIV+)	Columbia	Mar 2005–Dec 2006	2 yrs	502	≥10 mm = 331	37	Unclear how many cases were TST-positive
Giri et al. Occ Med 2014 ³³	Healthcare workers	UK	Apr 2009–Mar 2012	<3 yrs	788	≥6 mm = 191	0	N/A
Gourevitch et al. AIDS 1999 ³⁴	HIV+ (CD4 range 6-1980)	NYC	1985–1996	<11 yrs	431	≥5 mm = 202	25	16/25 (64%)
Guwatudde et al. AJE 2003 ³⁵	Contacts (age 0->35y; 10% HIV+)	Uganda	Oct 1995–Feb 1999	2 yrs	1206	≥5 mm = 963 ≥10 mm = 801	25	≥5 mm = 23/25 (92%) ≥10 mm = 20/25 (80%)
Harstad et al. IJTLD 2010 ²³	Adult asylum seekers	Norway	Sept 2005–Jun2006	23–32 mos.	823	≥6 mm = 426 ≥15 mm = 128	9	≥6mm = 8/9 (89%) ≥15 mm = 3/9 (33%)
Higuchi et al. Resp 2007 ⁸	School children	Japan	Dec 2002	3.5 yrs.	349	≥30 mm = 95	0	N/A
Higuchi et al. J Inf 2009 ³⁶	School children	Japan	Jan–Feb 2006	3 yrs.	306	≥5 mm = 200 ≥10 mm = 90	0	N/A
Hill et al. PLOS One 2008 ⁴	Close contacts >15y (2% HIV+)	Gambia	Jun 2002–Oct 2004	2 yrs.	2348	≥10 mm = 843	26	14/26 (54%)

Study	Group at High Risk	Country	Yr(s)	Duration of Follow-Up	Subjects, No.	Positive TST, No. (%)	Progressed to Active TB, No. (%)	TST Sensitivity for All Cases of Active TB
Jeyakumar et al. Med J Malaysia 1999 ³⁷	Nursing students	Malaysia	Jan 1994–Dec 1996	2 yrs	366	≥15 mm = 102	4	3/4 (75%)
Kim et al. AJT 2011 ²²	Renal transplant	Korea	Jun 2008–Dec 2009	>1 yrs	296	≥10 mm = 24	4	0/4 (0%)
Kruczak et al. Scand J Infect Dis 2014 ¹²	Homeless, contacts, and Long term care facility residents	Poland	Jul 2007–Sept 2009	4–5 yrs	701	>10 mm = 338	12	7/12 (58%)
Lee et al. Infection 2009 ¹⁹	End stage renal disease	Taiwan	Sept 2005	2 yrs	32	≥10 mm = 20	2	1/2 (50%)
Lee et al. Infection 2009 ¹⁹	Healthy controls	Taiwan	Sept 2005	2 yrs	32	≥10 mm = 21	0	N/A
Leow et al. Exp Clin Endo Diab 2014 ³⁸	Diabetics	Singapore	Feb 2007–Feb 2012	>1 yrs	220	≥10 mm = 63	0	N/A
Leung et al. Arch Ped Adol Med 2006 ³⁹	School children	Hong Kong	1999	4 yrs	656	≥20 mm = 656	10	10/10 (100%)
Leung et al. AJRCCM 2010 ²¹	Persons with Silicosis	Hong Kong	Dec 2004–Dec 2008	>1 yrs	308	>10 mm = 203	17	13/17 (76%)
Lienhardt et al. PLOS One 2010 ⁶	Contacts (>18y)	Senegal	Mar 2004–Apr 2006	2 yrs	2,458	≥10 mm = 1,591	52	39/52 (75%)
Mahomed et al. PLOS ONE 2011; ²⁴	Adolescents	South Africa	2005–2009	~2 yrs	5,244	≥10 mm = 2,894	52	40/52 (77%)
Markowitz et al.	HIV+ (median	U.S.	Nov	~4.5 yrs	1,130	≥5 mm = 66	28	8/28 (29%)

Study	Group at High Risk	Country	Yr(s)	Duration of Follow-Up	Subjects, No.	Positive TST, No. (%)	Progressed to Active TB, No. (%)	TST Sensitivity for All Cases of Active TB
Ann Int Med 1997 ⁴⁰	CD4+ 410)		1988–Feb 1990					
Pullar et al. BMC Inf Dis 2014 ¹³	HIV+ (CD4 ~40-488)	Norway	Jan 2009–Oct 2010	2 yrs	217	≥5 mm = 52	0	N/A
Rakotosamimanana et al. Eur Respir J 2015 ⁴¹	Contacts >1y, all HIV-	Madagascar	Unknown	18 mos.	289	≥14 mm = 123	12	10/12 (83%)
Doherty et al. JCM 2002 ⁴²	Contacts (<5% HIV+)	Ethiopia	Unknown	2 yrs	24	In vitro PPD stimulation	7	7/7 (100%)
Rueda et al. IJTLD 2014 ⁴³	Incarcerated men (<1% HIV+)	Colombia	Nov 2012–Dec 2013	1 yrs	829	643 (78%)	4	4/4 (100%)
Santin et al. Diag Micro and Inf Dis 2011 ¹⁴	HIV+ (Median CD4 = 300)	Spain	Mar 2007–Nov 2009	Median 600 days	135	≥5 mm = 9	0	N/A
Selwyn et al. JAMA 1992 ⁴⁴	HIV+ intravenous drug users	U.S.	Jun 1988–Dec 1990	31 mos.	120	≥5 mm HIV-positive = 52	5	0/5 (0%)
Sester et al. AJRCCM 2014; ¹⁸	HIV+ (Median CD4 302)	Europe	Jun 2008–May 2011	Median 1.8 yrs	768	≥5 mm = 67	10	4/10 (40%)
Silverman et al. Clin Biochem 2007 ⁴⁵	Bladder CA with BCG	Canada	Jun–Jul 2004	2 yrs	22	≥5 mm = 15	0	N/A
Song et al. Chest 2012 ¹⁰	School aged pediatric contacts	Korea	May–Jul 2007	2 yrs	1,826	≥10 mm = 270	21	11/21 (52%)
Thomas et al.	Children	Bangladesh	Apr–Jun	1 yr	302	≥10 mm = 101	0	N/A

Study	Group at High Risk	Country	Yr(s)	Duration of Follow-Up	Subjects, No.	Positive TST, No. (%)	Progressed to Active TB, No. (%)	TST Sensitivity for All Cases of Active TB
Pediatrics 2010 ⁴⁶			2009					
Wyndham–Thomas BMC Inf Dis 2015 ⁴⁷	HIV+ (Median CD4 517)	Belgium	Dec 2011–Dec 2012	1 yr	46	≥5 mm = 4	0	N/A
Joshi et al. Eur Resp J 2011 ⁴⁸	Healthcare workers	India	Jan–Jun 2004	6 yrs	719	TST- and QFT-IT positive = 217	14	6/14 (43%)
Yoshiyama et al. IJTLD 2010 ⁷	Contacts	Japan	2003–2005	~579 days	856	≥10 mm = 679	12	10/12 (83%)
Sloot et al. AJRCCM 2014 ⁴⁹	Contacts (~7% HIV+)	Netherlands	2002–2011	>10 mos.	4,774	≥10 mm = 681	18	14/18 (78%)
Mandalakas et al. AJRCCM 2015 ²⁶	Pediatric contacts aged 3m-15y (22% HIV+)	Cape Town, South Africa	2008–2012	3 mos.	1,343 (1,044 HIV-negative, 299 HIV-positive)	≥10 mm if HIV-negative = 436 ≥5 mm if HIV-positive = 93	85	57/85 (67%)

Abbreviations: HIV=human immunodeficiency virus; LTBI = latent tuberculosis infection; N/A = not applicable; QFT-IT = QuantiFERON® Gold In-tube; TB = tuberculosis; TST = tuberculin skin test.

Summary of Test Sensitivity (calculated as the proportion of TST- or IGRA-positive cases among those who progressed to active TB):

QFT-IT

HIV-negative, contacts

Range 51.3%–100%

Weighted average 80/109 (73.4%)

HIV-positive

Range 37.5%–100%

Weighted average 6/11 (54.5%)

Children<5

Only 1 study
54/76 (71.1%)

TSPOT

HIV-negative, contacts

Range 50%–75%

Weighted average 36/56 (64.3%)

HIV-positive

Range 40%–66.7%

Weighted average 10/19 (52.6%)

Children<5

Range 62.5%–73.3%

Weighted average 56/87 (64.4%)

TST

HIV-negative, contacts

Range 54%–100%

Weighted average 143/180 (79%)

HIV-positive

Range 0–64%

Weighted average 40/96 (42%)

Children<5

Range 52%–100%

Weighted average 1,490/1,531 (97%)

Exclude Comstock-90/131

Table S4. Combinations of Test Result for Participants, by Group (by Using Borderline as Negative, Cutoff of ≥ 8 spots = Positive for TSPOT)

Test Combination (TST/QFT/TSPOT)	FB, HIV-, 5+	FB, HIV-, <5	FB, HIV+, 5+	US, HIV-, 5+	US, HIV+, 5+
---	3,802	331	95	592	1,095
--+	62	0	0	4	4
-+-	186	2	8	22	54
-++	133	0	0	10	9
+-+	1,730	116	10	53	41
++-	136	0	0	5	0
+++	415	7	10	16	9
+++	1,467	8	17	73	14
Total	7,931	464	140	775	1,226

Abbreviations: FB = foreign-born; HIV = human immunodeficiency virus; 5+ = age 5 years and older; <5=under 5 years of age; TST=tuberculin skin test; QFT=QuantiFERON Gold in-tube; TSPOT=TSPOT.TB; +=positive test; -=negative test

Table S5. Estimated Prevalence and Test Characteristics Derived from the Three-Test, Random Effects Model by Using the U.S. TSPOT Cutoff in Specified Groups, Treating Borderline Results (5-, 6-, or 7-spot Difference) as Negative. Parameter Values Are Mean Estimates with 95% Credible Intervals in Parentheses

Parameter	FB, HIV-, 5+	FB, HIV-, <5	FB, HIV+, 5+	US, HIV-, 5+	US, HIV+, 5+
LTBI prevalence	34.0% (27.7–39.3)	3.6% (1.6–6.2)	15.2% (0.1–42.6)	17.3% (12.8–22.4)	3.9% (2.4–5.8)
TST					
Sensitivity	80.6% (72.5–90.5)	69.4% (58.7–80.0)	57.7% (47.9–68.2)	73.4% (62.7–85.4)	54.5% (45.0–64.9)
Specificity	70.0% (68.3–71.5)	73.7% (69.5–77.8)	79.0% (64.7–95.2)	92.2% (89.8–94.4)	96.4% (95.2–97.5)
QFT-IT					
Sensitivity	78.8% (69.5–90.2)	73.4% (57.0–88.1)	57.9% (38.6–74.7)	77.8% (64.4–91.1)	70.0% (55.3–83.9)
Specificity	98.5% (96.1–99.8)	98.8% (97.2–99.8)	82.7% (67.9–98.7)	97.6% (95.7–99.3)	95.7% (94.3–97.0)
TSPOT					
Sensitivity	73.5% (63.8–86.3)	56.7% (39.8–74.6)	47.2% (31.5–68.0)	66.1% (53.0–81.8)	52.5% (38.1–68.2)
Specificity	99.3% (98.0–99.9)	99.6% (98.8–99.9)	91.8% (81.9–99.7)	99.4% (98.5–99.9)	99.6% (99.1–99.9)

Abbreviations: HIV = human immunodeficiency virus; LTBI = latent tuberculosis infection; NPV = negative predictive value; PPV = positive predictive value; QFT-IT = QuantiFERON[®] Gold In-Tube; TSPOT = T-SPOT[®].TB; TST = tuberculin skin test.

Figure S1. Latent tuberculosis prevalence and test characteristics (sensitivity and specificity) by prespecified groups. On the x-axis, the label “CI” stands for the model that assumes conditional independence of the tests, “R” stands for the model that includes a random effect (to model conditional dependence between the tests), and “Prior” shows the literature-based prior distribution (for test sensitivity only). The horizontal lines in the center of the rectangles are the Bayesian posterior means, whereas the top and bottom lines in each box are the boundaries of the first and third quartiles, respectively. The tips of the vertical lines span the 95% credible interval for each parameter. For purposes of this analysis, TSPOT was evaluated by using the international criteria for a positive test (≥ 6 spots is positive; ≤ 5 spots is negative).

Abbreviations: CI=conditional independence model; prev = latent tuberculosis prevalence; Prior=scientific literature-based prior distribution (for test sensitivity only); R=random effect model; sensQFT = sensitivity of QuantiFERON[®] Gold In-Tube; sensTSPOT = sensitivity of T-SPOT[®].TB; sensTST = sensitivity of the tuberculin skin test; specQFT = specificity of QuantiFERON Gold In-Tube; specTSPOT = specificity of T-SPOT.TB[®]; specTST = specificity of the tuberculin skin test.

References

1. Zellweger JP, Sotgiu G, Block M, et al. Risk Assessment of Tuberculosis in Contacts by IFN-gamma Release Assays. A Tuberculosis Network European Trials Group Study. *Am J Respir Crit Care Med* 2015;191(10):1176-84. doi: 10.1164/rccm.201502-0232OC
2. Diel R, Loddenkemper R, Meywald-Walter K, et al. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with *Mycobacterium tuberculosis*. *Am J Respir Crit Care Med* 2008;177(10):1164-70. doi: 10.1164/rccm.200711-1613OC
3. Diel R, Goletti D, Ferrara G, et al. Interferon-gamma release assays for the diagnosis of latent *Mycobacterium tuberculosis* infection: a systematic review and meta-analysis. *Eur Respir J* 2011;37(1):88-99. doi: 10.1183/09031936.00115110
4. Hill PC, Jackson-Sillah DJ, Fox A, et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. *PLoS One* 2008;3(1):e1379. doi: 10.1371/journal.pone.0001379
5. Kik SV, Franken WP, Mensen M, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. *Eur Respir J* 2010;35(6):1346-53. doi: 10.1183/09031936.00098509
6. Lienhardt C, Fielding K, Hane AA, et al. Evaluation of the prognostic value of IFN-gamma release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal. *PLoS One* 2010;5(5):e10508. doi: 10.1371/journal.pone.0010508
7. Yoshiyama T, Harada N, Higuchi K, et al. Use of the QuantiFERON-TB Gold test for screening tuberculosis contacts and predicting active disease. *Int J Tuberc Lung Dis* 2010;14(7):819-27.
8. Higuchi K, Harada N, Mori T, et al. Use of QuantiFERON-TB Gold to investigate tuberculosis contacts in a high school. *Respirology* 2007;12(1):88-92. doi: 10.1111/j.1440-1843.2006.01000.x
9. Bradshaw L, Davies E, Devine M, et al. The role of the interferon gamma release assay in assessing recent tuberculosis transmission in a hospital incident. *PLoS One* 2011;6(6):e20770. doi: 10.1371/journal.pone.0020770

10. Song S, Jeon D, Kim JW, et al. Performance of confirmatory interferon-gamma release assays in school TB outbreaks. *Chest* 2012;141(4):983-88. doi: 10.1378/chest.11-1158
11. Bakir M, Millington KA, Soysal A, et al. Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. *Ann Intern Med* 2008;149(11):777-87.
12. Kruczak K, Duplaga M, Sanak M, et al. Comparison of IGRA tests and TST in the diagnosis of latent tuberculosis infection and predicting tuberculosis in risk groups in Krakow, Poland. *Scand J Infect Dis* 2014;46(9):649-55. doi: 10.3109/00365548.2014.927955
13. Pullar ND, Steinum H, Bruun JN, et al. HIV patients with latent tuberculosis living in a low-endemic country do not develop active disease during a 2 year follow-up; a Norwegian prospective multicenter study. *BMC infectious diseases* 2014;14:667. doi: 10.1186/s12879-014-0667-0
14. Santin M, Casas S, Saumoy M, et al. Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-gamma release assay, and the development of active tuberculosis in HIV-seropositive persons. *Diagn Microbiol Infect Dis* 2011;69(1):59-65. doi: 10.1016/j.diagmicrobio.2010.09.005
15. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. *Clin Infect Dis* 2009;48(7):954-62. doi: 10.1086/597351
16. Jonnalagadda S, Lohman Payne B, Brown E, et al. Latent tuberculosis detection by interferon gamma release assay during pregnancy predicts active tuberculosis and mortality in human immunodeficiency virus type 1-infected women and their children. *J Infect Dis* 2010;202(12):1826-35. doi: 10.1086/657411
17. Lange B, Vavra M, Kern WV, et al. Development of tuberculosis in immunocompromised patients with a positive tuberculosis-specific IGRA. *Int J Tuberc Lung Dis* 2012;16(4):492-5. doi: 10.5588/ijtld.11.0416
18. Sester M, van Leth F, Bruchfeld J, et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. *Am J Respir Crit Care Med* 2014;190(10):1168-76. doi: 10.1164/rccm.201405-0967OC

19. Lee SS, Chou KJ, Su IJ, et al. High prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: Comparison of QuantiFERON-TB GOLD, ELISPOT, and tuberculin skin test. *Infection* 2009;37(2):96-102. doi: 10.1007/s15010-008-8082-3
20. Chang B, Park HY, Jeon K, et al. Interferon-gamma release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. *Clin Rheumatol* 2011;30(12):1535-41. doi: 10.1007/s10067-011-1771-9
21. Leung CC, Yam WC, Yew WW, et al. T-Spot.TB outperforms tuberculin skin test in predicting tuberculosis disease. *Am J Respir Crit Care Med* 2010;182(6):834-40. doi: 10.1164/rccm.200912-1875OC
22. Kim SH, Lee SO, Park JB, et al. A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. *Am J Transplant* 2011;11(9):1927-35. doi: 10.1111/j.1600-6143.2011.03625.x
23. Harstad I, Winje BA, Heldal E, et al. Predictive values of QuantiFERON-TB Gold testing in screening for tuberculosis disease in asylum seekers. *Int J Tuberc Lung Dis* 2010;14(9):1209-11.
24. Mahomed H, Hawkrigde T, Verver S, et al. The tuberculin skin test versus QuantiFERON TB Gold(R) in predicting tuberculosis disease in an adolescent cohort study in South Africa. *PLoS One* 2011;6(3):e17984. doi: 10.1371/journal.pone.0017984
25. Schablon A, Diel R, Diner G, et al. Specificity of a whole blood IGRA in German nursing students. *BMC infectious diseases* 2011;11:245. doi: 10.1186/1471-2334-11-245
26. Mandalakas AM, Kirchner HL, Walzl G, et al. Optimizing the detection of recent tuberculosis infection in children in a high tuberculosis-HIV burden setting. *Am J Respir Crit Care Med* 2015;191(7):820-30. doi: 10.1164/rccm.201406-1165OC
27. Sackoff JE, Torian LV, Frieden TR. TB prevention in HIV clinics in New York City. *Int J Tuberc Lung Dis* 2001;5(2):123-8.
28. Zhang LF, Liu XQ, Zhang Y, et al. A prospective longitudinal study evaluating a T-cell-based assay for latent tuberculosis infection in health-care workers in a general hospital in Beijing. *Chin Med J (Engl)* 2013;126(11):2039-44.

29. Torres Costa J, Silva R, Ringshausen FC, et al. Screening for tuberculosis and prediction of disease in Portuguese healthcare workers. *J Occup Med Toxicol* 2011;6:19. doi: 10.1186/1745-6673-6-19
30. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. *Am J Epidemiol* 1974;99(2):131-8.
31. Daley CL, Hahn JA, Moss AR, et al. Incidence of tuberculosis in injection drug users in San Francisco: impact of anergy. *Am J Respir Crit Care Med* 1998;157(1):19-22. doi: 10.1164/ajrccm.157.1.9701111
32. del Corral H, Paris SC, Marin ND, et al. IFN γ response to *Mycobacterium tuberculosis*, risk of infection and disease in household contacts of tuberculosis patients in Colombia. *PLoS One* 2009;4(12):e8257. doi: 10.1371/journal.pone.0008257
33. Giri P, Basu S, Sargeant T, et al. Pre-placement screening for tuberculosis in healthcare workers. *Occup Med (Lond)* 2014;64(7):524-9. doi: 10.1093/occmed/kqu107
34. Gourevitch MN, Hartel D, Selwyn PA, et al. Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. *AIDS* 1999;13(15):2069-74.
35. Guwatudde D, Nakakeeto M, Jones-Lopez EC, et al. Tuberculosis in household contacts of infectious cases in Kampala, Uganda. *Am J Epidemiol* 2003;158(9):887-98.
36. Higuchi K, Kondo S, Wada M, et al. Contact investigation in a primary school using a whole blood interferon-gamma assay. *J Infect* 2009;58(5):352-7. doi: 10.1016/j.jinf.2009.02.019
37. Jeyakumar D. Tuberculin reactivity and subsequent development of tuberculosis in a cohort of student nurses. *Med J Malaysia* 1999;54(4):492-5.
38. Leow MK, Dalan R, Chee CB, et al. Latent tuberculosis in patients with diabetes mellitus: prevalence, progression and public health implications. *Exp Clin Endocrinol Diabetes* 2014;122(9):528-32. doi: 10.1055/s-0034-1377044
39. Leung CC, Yew WW, Chang KC, et al. Risk of active tuberculosis among schoolchildren in Hong Kong. *Arch Pediatr Adolesc Med* 2006;160(3):247-51. doi: 10.1001/archpedi.160.3.247

40. Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV-infected persons. The Pulmonary Complications of HIV Infection Study Group. *Ann Intern Med* 1997;126(2):123-32.
41. Rakotosamimanana N, Richard V, Raharimanga V, et al. Biomarkers for risk of developing active tuberculosis in contacts of TB patients: a prospective cohort study. *Eur Respir J* 2015;46(4):1095-103. doi: 10.1183/13993003.00263-2015
42. Doherty TM, Demissie A, Olobo J, et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. *J Clin Microbiol* 2002;40(2):704-6.
43. Rueda ZV, Arroyave L, Marin D, et al. High prevalence and risk factors associated with latent tuberculous infection in two Colombian prisons. *Int J Tuberc Lung Dis* 2014;18(10):1166-71. doi: 10.5588/ijtld.14.0179
44. Selwyn PA, Sckell BM, Alcabes P, et al. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. *JAMA* 1992;268(4):504-9.
45. Silverman MS, Reynolds D, Kavsak PA, et al. Use of an interferon-gamma based assay to assess bladder cancer patients treated with intravesical BCG and exposed to tuberculosis. *Clin Biochem* 2007;40(12):913-5. doi: 10.1016/j.clinbiochem.2007.04.006
46. Thomas TA, Mondal D, Noor Z, et al. Malnutrition and helminth infection affect performance of an interferon gamma-release assay. *Pediatrics* 2010;126(6):e1522-9. doi: 10.1542/peds.2010-0885
47. Wyndham-Thomas C, Dirix V, Schepers K, et al. Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON-TB Gold In-tube. *BMC infectious diseases* 2015;15:59. doi: 10.1186/s12879-015-0796-0
48. Joshi R, Narang U, Zwerling A, et al. Predictive value of latent tuberculosis tests in Indian healthcare workers: a cohort study. *Eur Respir J* 2011;38(6):1475-7. doi: 10.1183/09031936.00014611

49. Sloot R, Schim van der Loeff MF, Kouw PM, et al. Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam. *Am J Respir Crit Care Med* 2014;190(9):1044-52. doi: 10.1164/rccm.201406-1159OC